---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261799"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:55:31.646964+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan reports Phase 1 CLN-049 data: 31% CRc at 12 μg/kg in r/r AML

## Summary
- Anti-leukemic activity at doses ≥6 μg/kg: CRc 30%, ORR 57% (n=23); at 12 μg/kg CRc 31%, ORR 69% (n=13).
- Responses across genetic risk; in TP53-mutated AML 4/5 patients responded (2 CRh, 2 MLFS) at 12 μg/kg.
- Safety manageable: all CRS Grade 1-2; no discontinuations due to CRS or ICANS. Common TEAEs: CRS 40%, IRR 35%.
- Oral presentation at ASH on Dec 8, 2025; dose escalation ongoing. Company to host investor event Dec 8.

## SEC filing metadata
- accession: 0001193125-25-261799
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312525261799/0001193125-25-261799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312525261799/cgem-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261799
- JSON: https://secwatch.observer/filing/0001193125-25-261799.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.